The Use of Functional Magnetic Resonance Imaging to Test Pharmacotherapies for Alcohol Use Disorder: A Systematic Review

Erica N. Grodin and Lara A. Ray

Alcohol use disorder (AUD) is a chronic relapsing condition that represents a significant public health concern. Pharmacological treatment development for AUD is a top research priority, and many studies are being conducted to evaluate potential AUD treatments. Understanding the brain circuitry impacted by addiction is crucial for the development of efficacious pharmacological interventions. These neuroadaptations can be probed noninvasively using functional magnetic resonance neuroimaging (fMRI). fMRI may be an effective tool to identify biomarkers for AUD pharmacotherapies, evaluating changes associated with pharmacological treatment. Thus, the present qualitative review of the literature focuses on the role of fMRI as a tool for medication development for AUD. The aim of this review was to assemble research across a range of fMRI paradigms to study the effectiveness of pharmacological treatments of adult AUD. First, we present a qualitative review of fMRI AUD pharmacotherapy studies, differentiating studies based on their dosing regimen. Second, we provide recommendations for the field to improve the use of fMRI as a biomarker for AUD pharmacotherapy.

Key Words: Alcohol Use Disorder, Functional Magnetic Resonance Imaging, Pharmacotherapy, Medication Development, Treatment.
changes associated with pharmacological treatment beyond what can be obtained from self-report or clinical outcome measures. To that end, the present qualitative review of the literature focuses on the role of fMRI as a tool for medication development for AUD.

The most common image contrast used in fMRI is the blood-oxygen-level-dependent (BOLD) contrast. fMRI exploits coupling in the brain between neuronal activity and hemodynamics to noninvasively localize and measure brain activity (Heeger and Ress, 2002). Specifically, increases in neuronal activity are associated with increases in regional cerebral blood flow, which are accompanied by small changes in oxygen consumption (Fox and Raichle, 1986; Hoge et al., 1999). Alterations in vascular occupancy, oxygen supply, and oxygen consumption result in an increased concentration of diamagnetic oxyhemoglobin and a decreased quantity of paramagnetic deoxyhemoglobin in the blood (Buxton et al., 2004; Iannetti and Wise, 2007). This produces a net decrease in the magnetic field around the blood vessels which can be detected through the BOLD contrast. While BOLD signal highly correlated with neural activity (Logothetis, 2003; Mukamel et al., 2005), changes in BOLD signal may be influenced by the pharmacological treatment which is being studied (Iannetti and Wise, 2007).

For example, a pharmacotherapy may alter the efficiency of the signaling between neurons and blood vessels, which would reduce the BOLD signal response to a stimulus. If the pharmacotherapy’s effect on the hemodynamic response is not taken into account, the results of the study may be incorrectly interrupted as an effect of the medication on neural activity (Iannetti and Wise, 2007). This confound can be evaluated and corrected through the collection of an arterial spin labeling (ASL) scan to evaluate the overall effect of a medication on cerebral blood flow. However, the majority of pharmacotherapy neuroimaging studies do not currently employ this correction method.

Several fMRI paradigms have been developed to investigate brain circuits putatively involved in AUD. The most commonly used paradigm is alcohol cue reactivity, where alcohol-associated stimuli are presented to induce an alcohol craving response (Monti et al., 1987). Cue-reactivity paradigms have been widely adapted for neuroimaging protocols, and studies suggest that cue reactivity engages learning and memory circuits as well as reward circuitry, and fMRI studies have reliably shown activation in regions including the ventral striatum (VS), prefrontal cortex (PFC), cingulate, insula, and precuneus (Courtney et al., 2016; Schacht et al., 2013a). The neural processing of nondrug reward, which is thought to be maladaptively decreased in individuals with AUD, has been commonly measured using the monetary incentive delay (MID) task (Knutson et al., 2001). In the MID task, participants are presented with abstract stimuli which indicate the reward trial type; participants then view a target, which is presented for a short period of time. During the presentation of the target, they must press a button in order to receive the reward. Finally, they view feedback on the success of the trial (Knutson et al., 2001). There have been divergent findings using the MID task in AUD populations; however, several studies have reported a decrease in VS activation in response to monetary reward anticipation in individuals with AUD compared to controls (Balodis and Potenza, 2015). Inhibitory control, which has also been suggested to be pathologically low in individuals with AUD, has been commonly evaluated with the Go/No-Go (GNG) and stop signal tasks (SST). Both the GNG and SS tasks create conflict conditions in which an individual must inhibit a prepotent motor response. Task difficulty is modulated such that withholding the motor response is challenging and thus requires inhibitory control processing. Individuals with addictive disorders consistently show hypoactivation of brain circuits involved in executive control and memory, as well as decreased recruitment of the salience network during conflict processing, when inhibitory control is required (Zilverstand et al., 2018). Yet, another dimension that has been implicated in AUD is negative emotionality, where negative affective states such as dysphoria and anhedonia are commonly reported, particularly during alcohol withdrawal and withdrawal-induced alcohol craving. Emotional processing has been evaluated using 2 fMRI visual stimulus sets: 1 using positive, negative, and neutral stimuli from the International Affective Picture System (IAPS), and the other presenting emotional face stimuli. Typically, participants are asked to passively view images from each group of stimuli; in some studies, participants are asked to press a button during specific times during the scan to ensure attention. Finally, delay discounting tasks measure intertemporal choice behavior, where individuals must choose between smaller immediate rewards and larger delayed rewards, and are considered a behavioral index of impulsivity (MacKillip, 2016). Together, this array of neuroimaging tasks seeks to capture AUD-relevant pathophysiology and associated neural activation, in turn providing an opportunity to test the effects of AUD pharmacotherapies on these processes (see Fig. 1).

While several reviews and meta-analyses have examined alcohol cue-elicited neural processes (Buhler and Mann, 2011; Courtney et al., 2016; Schacht et al., 2013a; Yalachkov et al., 2012), only 2 reviews have examined the use of neuroimaging methods to evaluate substance use disorder treatments (Cabrera et al., 2016; Courtney et al., 2016). Both previous reviews of substance disorder treatments focused broadly on all substances of abuse and are not specific to AUD. Further, Courtney and colleagues only included studies which employed a cue-reactivity paradigm, which limited their study selection (Courtney et al., 2016). To our knowledge, there have been no reviews that focus solely on the role of fMRI as a tool to investigate pharmacotherapies in AUD. Therefore, the aim of this review was to assemble research across a range of fMRI paradigms to study the effectiveness of pharmacological treatments of adult AUD. The goal of this review is 2-fold. First, we present a qualitative review of fMRI AUD pharmacotherapy studies, describing the main findings from studies that administered pharmacotherapies
chronically, that is, for 6 or more days prior to the fMRI scan, and studies that administered pharmacotherapies in a single dose prior to the fMRI scan. Second, we provide recommendations for the field to improve the use of fMRI as a biomarker for AUD pharmacotherapy.

MATERIALS AND METHODS

Literature Search and Selection

Published papers were identified using the PubMed database (https://www.ncbi.nlm.nih.gov/pubmed). The keywords used in the search were as follows: ‘fMRI’, ‘functional magnetic resonance imaging’, and ‘alcohol’. The reference sections of identified papers were also consulted to identify additional relevant papers. Studies were included in this review if they were original investigations of individuals with AUD, treatment-seeking or non-treatment-seeking, or heavy drinkers, with or without an AUD, published in the English language, which used fMRI, and included a pharmacological treatment for AUD. Studies which were excluded from this review include review papers, studies in languages other than English, studies using animals, studies using other imaging modalities (structural MRI, positron emission tomography, magnetic resonance spectroscopy), studies that did not use an fMRI task (e.g., resting state fMRI), studies that examined the effect of alcohol infusion on brain function without the inclusion of a pharmacological treatment, studies of AUD pharmacotherapies in light drinkers or non-drinkers, and studies that examined psychosocial treatments without the combination of a pharmacotherapy. This search yielded 32 total studies, with 22 studies examining the effect of chronic dosing of AUD pharmacotherapies, with studies evaluating the effect of NTX \((n = 6)\), varenicline \((n = 3)\), baclofen \((n = 4)\), aripiprazole \((n = 3)\), CRF1 receptor antagonists \((n = 2)\), NK1 antagonists \((n = 2)\), acamprosate \((n = 1)\), and an NMDA agonist \((n = 1)\) on neural activation. Ten studies examined the effect of a single dose of AUD pharmacotherapies, with studies evaluating the effect of NTX \((n = 4)\), nalmefene \((n = 1)\), dopamine antagonists \((n = 2)\), modafinil \((n = 2)\), and oxytocin \((n = 1)\) on brain activation (see Fig. 2 for PRISMA diagram).

RESULTS

In reviewing the literature, it became clear that from a pharmacological viewpoint, studies differed markedly with regard to the medication dosing regimen prior to the fMRI assessment. Therefore, in this review we differentiate between studies in which pharmacotherapies were administered chronically (defined as medication administration for 6 or more days prior to the fMRI scan), and studies that administered pharmacotherapies in a single dose prior to the fMRI scan. On average, participants in the chronic dosing AUD pharmacotherapy studies were 36.50 ± 8.11 years old. Five studies enrolled non–treatment-seeking individuals with alcohol dependence (AD) or AUD, 2 studies enrolled non–treatment-seeking heavy drinkers, and the remaining 15 studies enrolled treatment-seeking individuals with AD or AUD. Of note, given that the nomenclature for alcohol use disorder has shifted from DSM-IV-TR to DSM-5, this review uses the diagnostic nomenclature provided by the primary source article. Participants were on active study medication for 16.23 ± 7.30 days prior to the fMRI scan (range = 6 to 42 days).

Regarding single dosing studies, on average, participants were 41.59 ± 8.97 years old. The majority of studies (8) enrolled abstinent individuals with AD or AUD, while 1 study involved alcohol infusion and enrolled non–treatment-seeking individuals with AD and 1 study enrolled non–

![Brain circuits implicated in AUD](image-url)

**Fig. 1.** Brain circuits implicated in AUD. Three domains implicated in AUD are displayed (purple = reward processing; green = negative emotionality; and blue = inhibitory control). fMRI tasks used to probe these domains are listed below the domain, and major brain regions targeted within these tasks are highlighted. Brain regions that are involved in multiple domains are listed in 2 colors. Abbreviations: dIPFC, dorsolateral prefrontal cortex; vIPFC, ventrolateral prefrontal cortex; ACC, anterior cingulate cortex; OFC, orbitofrontal cortex; VS, ventral striatum.
treatment-seeking heavy drinkers. Participants were administered the study drug 2.08 ± 0.74 hours prior to the MRI scan (range = 45 minutes to 4 hours).

Studies of AUD Pharmacotherapies Administered Chronically

We begin with a review of the studies in which pharmacotherapies were administered chronically. In doing so, it is important to recognize that the definition of chronic administration is arbitrary in that from a pharmacological viewpoint, a 6-day administration is fairly short. However, the assumption underlying these studies is that a steady state on the given medication has been reached, allowing for meaningful testing of neuroimaging parameters. Furthermore, different medications have different titration (i.e., dosing up) protocols which in turn would impact the feasibility of single-dose testing and by definition, would require a lengthier dose-escalation procedure. All of the chronic dosing studies employed a between-subjects approach, where participants were randomized to receive the active medication or a matched placebo control. With those considerations in mind, the following is a summary of the key findings by each medication administered chronically, across a range of fMRI tasks (see Table 1).

Naltrexone, an opioid antagonist with the greatest selectivity for μ- and κ-opioid receptors and FDA-approved to treat AUD (Niciu and Arias, 2013), has been the most widely studied pharmacotherapy for AUD in the context of neuroimaging. Six studies examined the ability of NTX to modulate reward and affective neural processes in individuals with AUD (Bach et al., 2019; Lukas et al., 2013; Myrick et al., 2008; Schacht et al., 2013c, 2017; Spagnolo et al., 2014). The first neuroimaging study of NTX was conducted by Myrick and colleagues, who investigated the effect of NTX, ondansetron (OND), which is a selective 5HT-3 antagonist (Akbar et al., 2018), and the combination of NTX and ondansetron (NTX + OND) on neural alcohol cue reactivity (Myrick et al., 2008). They found that while individuals on the placebo control reliably demonstrated ventral striatal activation in response to alcohol cues, NTX, OND, and NTX + OND abolished this reward activation response. Further, the combination of NTX + OND resulted in a reduction in alcohol cue-induced craving compared with placebo. Schacht and colleagues also found that 2 weeks of NTX reduced right VS activation in response to alcohol cues compared with placebo (Schacht et al., 2017). Additionally, they reported an interaction between VS activation and medication in predicting heavy drinking, such that NTX-treated individuals who had the greatest reductions in VS activation experienced the fewest heavy drinking in the 14 weeks following the scan. However, these findings are in contrast with an earlier study conducted by the same group, where they did not find a main effect of NTX on alcohol cue-elicited activation in the VS or in 2 other region of interests (ROIs): the medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC) (Schacht et al., 2013c). This study did find a
Table 1. AUD Pharmacotherapy Studies with Chronic Dosing

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Medication, dose, duration</th>
<th>fMRI task</th>
<th>Active (drug) N</th>
<th>Control (placebo) N</th>
<th>Population type</th>
<th>Scan timing</th>
<th>Analysis approach</th>
<th>Results</th>
<th>Clinical outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naltrexone (NTX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myrick et al. (2008)</td>
<td>50 mg NTX × 7 days</td>
<td>Visual alcohol cues</td>
<td>23</td>
<td>24</td>
<td>NTS AD</td>
<td>Post</td>
<td>Whole brain</td>
<td>NTX reduced activation to alcohol cues in ventral striatum.</td>
<td>NS (craving)</td>
</tr>
<tr>
<td></td>
<td>0.5 mg OND × 7 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OND reduced activation to alcohol cues in ventral striatum.</td>
<td>NS (craving)</td>
</tr>
<tr>
<td></td>
<td>50 mg NTX + 0.5 mg OND × 7 days</td>
<td>Visual alcohol cues</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NTX + OND reduced activation to alcohol cues in ventral striatum.</td>
<td>NTX + OND reduced in-scanner craving ratings.</td>
</tr>
<tr>
<td>Schacht et al. (2013b)</td>
<td>50 mg NTX × 6 days</td>
<td>Visual alcohol cues</td>
<td>35</td>
<td>39</td>
<td>NTS AD</td>
<td>Post</td>
<td>ROI</td>
<td>No significant effect of NTX or OPRM1 genotype on activation in regions of interest: VS, mPFC, OFC. NTX and OPRM1 genotype interacted; NTX-treated G-allele carriers had less OFC activation than A-allele homozygotes.</td>
<td>NP</td>
</tr>
<tr>
<td>Lukas et al. (2013)</td>
<td>380 mg extended-release NTX (single dose delivered 14 days prior to scanning)</td>
<td>Visual and olfactory alcohol cues</td>
<td>15</td>
<td>13</td>
<td>TS detoxed AD</td>
<td>Pre, post</td>
<td>Whole brain</td>
<td>NTX reduced activation in orbital gyri, cingulate, inferior frontal gyrus, and middle frontal gyrus to visual alcohol cues compared with placebo. NTX reduced activation in superior frontal gyrus, supramarginal gyrus, postcentral gyrus, and angular gyrus to alcohol odors compared with placebo.</td>
<td>XR-NTX reduced in-scanner craving ratings.</td>
</tr>
<tr>
<td>Schacht et al. (2017)</td>
<td>50 mg NTX × 14 days</td>
<td>Visual alcohol cues</td>
<td>59</td>
<td>57</td>
<td>TS AD</td>
<td>Pre, post</td>
<td>ROI</td>
<td>NTX reduced right ventral striatal activation to alcohol cues compared with placebo. NTX-treated individuals with large reductions in pre-post VS activation had less heavy drinking compared with placebo.</td>
<td>NTX-treated individuals with positive cue reactivity in the putamen had a longer time to relapse compared with placebo.</td>
</tr>
<tr>
<td>Bach et al. (2019)</td>
<td>Open-label NTX × 14 days</td>
<td>Visual alcohol cues</td>
<td>22</td>
<td>13</td>
<td>TS detoxed AD</td>
<td>Pre, post</td>
<td>Whole brain and ROI</td>
<td>NTX reduced alcohol cue-elicited activation in the putamen compared with the nonpharmacological withdrawal treatment group.</td>
<td>NTX-treated individuals with positive cue reactivity in the putamen had a longer time to relapse compared with placebo.</td>
</tr>
<tr>
<td>Spagnolo et al. (2014)</td>
<td>50 mg NTX × 9 days</td>
<td>Affective faces + alcohol infusion</td>
<td>31</td>
<td>32</td>
<td>TS AD</td>
<td>Post</td>
<td>ROI</td>
<td>NTX increased activation in ventral striatum to all stimuli compared with placebo. NTX + alcohol infusion increased ratings of intoxicated and high compared with placebo.</td>
<td>NTX + alcohol infusion increased ratings of intoxicated and high compared with placebo.</td>
</tr>
<tr>
<td>Varenicline (VAR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued.
<table>
<thead>
<tr>
<th>First author, year</th>
<th>Medication, dose, duration</th>
<th>fMRI task</th>
<th>Active ( (\text{drug}) ) ( N )</th>
<th>Control ( (\text{placebo}) ) ( N )</th>
<th>Population type</th>
<th>Scan timing</th>
<th>Analysis approach</th>
<th>Results</th>
<th>Clinical outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schacht et al. (2014)</td>
<td>2 mg varenicline ( \times ) 14 days</td>
<td>Visual alcohol cues</td>
<td>18</td>
<td>17</td>
<td>NTS AD</td>
<td>Post</td>
<td>ROI</td>
<td>VAR reduced activation in bilateral OFC compared with placebo.</td>
<td>NS (heavy drinking and craving)</td>
</tr>
<tr>
<td>Vatsalya et al. (2015)</td>
<td>2 mg varenicline ( \times ) 14 days</td>
<td>Alcohol food incentive delay task</td>
<td>17</td>
<td>12</td>
<td>NTS HD</td>
<td>Post</td>
<td>Whole brain and ROI</td>
<td>VAR reduced activation in striatum, insula, and amygdala during alcohol anticipation compared with placebo.</td>
<td>NP</td>
</tr>
<tr>
<td>Gowin et al. (2016)</td>
<td>2 mg varenicline ( \times ) 14 days</td>
<td>Affective faces + alcohol infusion</td>
<td>17</td>
<td>15</td>
<td>NTS HD</td>
<td>Post</td>
<td>Whole brain and ROI</td>
<td>VAR reduced activation in left amygdala when viewing fearful faces compared with placebo.</td>
<td>NP</td>
</tr>
<tr>
<td>Anticonvulsants (Gabapentin and Baclofen)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schacht et al. (2013a)</td>
<td>1,200 mg Gabapentin (maximum dose) ( \times ) 21 days + 2 mg infusions of flumazenil ( \times ) 2 days</td>
<td>Visual alcohol cues</td>
<td>28</td>
<td>20</td>
<td>TS AD</td>
<td>Post</td>
<td>Whole brain</td>
<td>No significant main effect of medication. In individuals with high levels of alcohol withdrawal, GBP increased activation in ACC in response to alcohol cues compared with placebo.</td>
<td>NS (heavy drinking)</td>
</tr>
<tr>
<td>Beck et al. (2018)</td>
<td>30 to 270 mg baclofen ( \times ) 14 days (individually titrated, mean dose = 138 mg)</td>
<td>Visual alcohol cues</td>
<td>10</td>
<td>13</td>
<td>TS detoxed AD</td>
<td>Pre, post</td>
<td>ROI</td>
<td>BAC decreased activation in left OFC, bilateral amygdala, and left VTA compared with placebo.</td>
<td>BAC reduced relapse rates. fMRI + BAC clinical outcomes NP</td>
</tr>
<tr>
<td>Holla et al. (2018)</td>
<td>60 mg baclofen ( \times ) 17 days</td>
<td>Visual alcohol cues</td>
<td>23</td>
<td>n/a</td>
<td>TS AUD</td>
<td>Pre, post</td>
<td>Whole brain and ROI</td>
<td>BAC increased activation in bilateral DLPFC and right ACC, and decreased activation in right insula compared to control group with AUD.</td>
<td>In BAC-treated individuals, increased ACC activation and decreased insula activation had longer time to alcohol relapse compared with placebo. BAC treatment abolished association between activation in caudate and heavy drinking.</td>
</tr>
<tr>
<td>Logge et al. (2019)</td>
<td>30 mg baclofen (low dose) or 74 mg baclofen (high dose) ( \times ) 17 days</td>
<td>Visual alcohol cues</td>
<td>11 (low dose)</td>
<td>11</td>
<td>TS AD</td>
<td>Post</td>
<td>Whole brain</td>
<td>No significant group differences for low-dose baclofen compared with placebo. High-dose BAC decreased activation to alcohol cues in the DLPFC, mPFC, and ACC compared with placebo.</td>
<td></td>
</tr>
<tr>
<td>Aripiprazole (APZ)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myrick et al. (2010)</td>
<td>15 mg aripiprazole ( \times ) 14 days</td>
<td>Visual alcohol cues</td>
<td>14</td>
<td>16</td>
<td>NTS AD</td>
<td>Post</td>
<td>ROI</td>
<td>APZ reduced activation in left VTA and right VS compared with placebo group.</td>
<td>APZ decreased heavy drinking compared with placebo. fMRI + AP clinical outcomes NP.</td>
</tr>
</tbody>
</table>
Table 1. (Continued)

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Medication, dose, duration</th>
<th>fMRI task</th>
<th>Active (drug) N</th>
<th>Control (placebo) N</th>
<th>Population type</th>
<th>Scan timing</th>
<th>Analysis approach</th>
<th>Results</th>
<th>Clinical outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Han et al. (2013)</td>
<td>15 mg aripiprazole + 20 mg Escitalopram (ESC) × 42 days</td>
<td>Video alcohol cues</td>
<td>14</td>
<td>17</td>
<td>TS detoxed AD with comorbid MDD</td>
<td>Pre, post</td>
<td>Whole brain</td>
<td>APZ + ESC increased activation in left ACC compared with ESC alone.</td>
<td>APZ + ESC reduced ratings of alcohol craving. fMRI + AP clinical outcomes NP. APZ interacted with DAT1 genotype; in 9R carriers, APZ reduced VS activation, whereas in 10R homozygotes, APZ increased VS activation to alcohol cues compared with placebo.</td>
</tr>
<tr>
<td>Schacht et al. (2018)</td>
<td>15 mg aripiprazole × 7 days</td>
<td>Visual alcohol cues</td>
<td>38</td>
<td>43</td>
<td>NTS AUD</td>
<td>Post</td>
<td>ROI</td>
<td>No significant effect of PEX on alcohol cue reactivity. No significant effect of PEX on neural processing of negative images. No significant effect of PEX on neural processing of affective stimuli.</td>
<td>Mixed effects, VER reduced activation in some frontal, temporal, and occipital regions, and increased activation in other frontal and temporal regions compared with placebo. No significant medication effects. VER reduced activation in right amygdala to fearful faces compared with placebo.</td>
</tr>
<tr>
<td>CRF1 Antagonists (Pexacerfont and Verucerfont) Kwako et al. (2015b)</td>
<td>1,000 mg pexacerfont (PEX) × 21 days</td>
<td>Visual alcohol cues IAPS</td>
<td>29</td>
<td>26</td>
<td>TS detoxed AD</td>
<td>Post</td>
<td>Whole brain</td>
<td>No significant effect of PEX on alcohol cue reactivity. No significant effect of PEX on neural processing of negative images. No significant effect of PEX on neural processing of affective stimuli.</td>
<td>NP</td>
</tr>
<tr>
<td>Schwandt et al. (2016)</td>
<td>350 mg verucerfont (VER) × 21 days</td>
<td>Visual alcohol cues IAPS</td>
<td>18</td>
<td>21</td>
<td>TS detoxed AD</td>
<td>Post</td>
<td>Whole brain</td>
<td>Mixed effects, VER reduced activation in some frontal, temporal, and occipital regions, and increased activation in other frontal and temporal regions compared with placebo. No significant medication effects. VER reduced activation in right amygdala to fearful faces compared with placebo.</td>
<td>NP</td>
</tr>
<tr>
<td>NK1 Antagonists (LY686017 and Aprepitant) George et al. (2008)</td>
<td>50 mg LY686017 × 21 days</td>
<td>Visual alcohol cues IAPS</td>
<td>25</td>
<td>25</td>
<td>TS detoxed AD</td>
<td>Post</td>
<td>Whole brain</td>
<td>No significant medication effect. LY686017 reduced activation to negative images in insula and occipital regions compared with placebo.</td>
<td>LY686017 decreased ratings of craving compared with placebo. fMRI + LY686017 clinical outcomes NP.</td>
</tr>
</tbody>
</table>
### Table 1. (Continued)

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Medication, dose, duration</th>
<th>fMRI task</th>
<th>Active (drug) N</th>
<th>Control (placebo) N</th>
<th>Population type</th>
<th>Scan timing</th>
<th>Analysis approach</th>
<th>Results</th>
<th>Clinical outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kwako et al. (2015a)</td>
<td>125 mg aprepitant (APREP) × 21 days</td>
<td>Visual alcohol cues</td>
<td>26</td>
<td>27</td>
<td>TS detoxed AD with PTSD</td>
<td>Post</td>
<td>Whole brain</td>
<td>No significant effects of APREP on neural alcohol cue reactivity. APREP increased activation to negative affective stimuli in bilateral vmPFC compared with placebo. No significant medication effects on activation to affective faces.</td>
<td>NP</td>
</tr>
<tr>
<td>Langosch et al. (2012)</td>
<td>1,998 mg acamprosate × 14 days</td>
<td>Visual alcohol cues</td>
<td>12</td>
<td>10</td>
<td>TS AD</td>
<td>Pre, post</td>
<td>Whole brain and ROI</td>
<td>No significant effect of acamprosate on modulating BOLD response to alcohol cues.</td>
<td>NP</td>
</tr>
<tr>
<td>Kiefer et al. (2015)</td>
<td>50 mg D-cycloserine × 21 days</td>
<td>Visual alcohol cues</td>
<td>16</td>
<td>16</td>
<td>TS detoxed AD</td>
<td>Pre, post</td>
<td>Whole brain</td>
<td>DCS combined with cue exposure-based extinction training (CET) reduced activation in ventral and dorsal striatum compared with CET alone. DCS + CET was more efficacious in individuals with high pretreatment VS activation and high craving, compared with placebo.</td>
<td></td>
</tr>
</tbody>
</table>

ACC, anterior cingulate cortex; AD, alcohol dependence (DSM-IV TR diagnosis); APREP, aprepitant; APZ, aripiprazole; AUD, alcohol use disorder (DSM-5 diagnosis); BAC, baclofen; DCS, D-cycloserine; DLPFC, dorsolateral prefrontal cortex; GBP, gabapentin; HD, heavy drinker; MDD, major depressive disorder; mPFC, medial prefrontal cortex; NP, clinical outcomes not present; NS, non-significant effect of drug on clinical outcomes; NTS, non-treatment-seeking; NTX, naltrexone; OFC, orbitofrontal cortex; OND, ondansetron; PEX, pexacerfont; PTSD, posttraumatic stress disorder; ROI, region of interest; TS, treatment-seeking; VAR, varenicline; VER, verucerfont; vmPFC, ventromedial prefrontal cortex; VS, ventral striatum; VTA, ventral tegmental area.

*Studies using the same study population.
moderating effect of genetic polymorphisms in the \( \mu \)-opioid receptor gene (OPRM1) and in the dopamine transporter gene (DAT1/SLC6A3) on response to NTX in the VS (Schacht et al., 2013c). Bach and colleagues evaluated the ability of NTX to block the incubation of alcohol-elicited cue reactivity (Bach et al., 2019). Open-label NTX significantly attenuated alcohol cue-elicited activation in the left putamen compared with a standard treatment group. Moreover, NTX-treated patients with positive cue reactivity at baseline, that is, individuals who had increased activation to alcohol compared with neutral cues, had a longer time to severe relapse than NTX-treated patients with negative cue reactivity at baseline or patients in the standard treatment group (Bach et al., 2019). Lukas and colleagues evaluated the effect of extended-release NTX (XR-NTX), a formulation of NTX administered through intramuscular injection once monthly, on neural response to visual and olfactory alcohol cues (Lukas et al., 2013). XR-NTX significantly attenuated activation in brain regions implicated in processing salience (cingulate, inferior frontal gyrus, orbital gyri) to visual and olfactory alcohol cues. However, these regions do not exhibit overlap with other studies of neuroimaging studies of NTX and alcohol cue reactivity. Similar to Myrick and colleagues (Myrick et al., 2008), treatment with XR-NTX reduced subjective reports of wanting alcohol during the fMRI scan (Lukas et al., 2013). One study employed a different methodology, using an intravenous alcohol infusion to investigate the effects of NTX on alcohol-induced activation in response to affective stimuli (Spagnolo et al., 2014). Contrary to earlier studies, Spagnolo and colleagues found that irrespective of alcohol infusion condition, NTX increased activation in the VS compared with placebo across affective stimuli. Also in contrast to other studies, Spagnolo and colleagues found that treatment with NTX increased ratings of alcohol craving after the presentation of alcohol cues compared with placebo. Overall, NTX appears to modulate reward circuitry, with the majority of studies reporting decreased activation in regions responsible for reward and salience during alcohol cue reactivity.

Varenicline, a full \( \alpha 7 \) nicotinic acetylcholine receptor agonist and a partial agonist to the \( \alpha 4\beta 2, \alpha 3\beta 4, \) and \( \alpha 6\beta 2 \) subtypes (Akbar et al., 2018; Mihalak et al., 2006), is FDA-approved for smoking cessation and has shown promise as an AUD pharmacotherapy. Three studies have investigated the effect of varenicline on neural activation to alcohol cues and affective stimuli (Gowin et al., 2016; Schacht et al., 2014; Vatsalya et al., 2015). Schacht and colleagues investigated the effect of varenicline on alcohol cue-elicited activation in regions implicated in reward processing (Schacht et al., 2014). Utilizing an ROI approach, they found that varenicline significantly reduced alcohol cue-elicited activation in the OFC, but did not modulate activity in the VS or mPFC. Treatment with varenicline did not reduce drinking or smoking during the 2-week trial, but did decrease alcohol craving compared with placebo (Schacht et al., 2014). Vatsalya and colleagues also examined the effect of varenicline on reward processing, using a modification of the MID task, in which alcohol and food rewards were substituted for the traditional monetary rewards (Vatsalya et al., 2015). They found that varenicline significantly reduced activation in the striatum, amygdala, and posterior insula in response to the anticipation of alcohol reward. Finally, Gowin and colleagues investigated the effect of varenicline on affective processing using fearful face stimuli (Gowin et al., 2016). They found that varenicline significantly attenuated amygdala activation to fearful faces compared with placebo. It should be noted that the Vatsalya and Gowin studies report subcomponents from the same larger study, that is, they used the same participants within their analyses. Together, these studies indicate that varenicline modulates reward circuitry in response to alcohol cues and may also attenuate negative emotional responses to fearful faces.

Several studies have investigated the effect of anticonvulsant medications on neural alcohol cue reactivity (Beck et al., 2018; Holla et al., 2018; Logge et al., 2019; Schacht et al., 2013b). Schacht and colleagues investigated the effect of a combination of flumazenil (FMZ), a \( \gamma \)-aminobutyric acid (GABA)\_\_ receptor antagonist, and gabapentin (GBP), a GABA analogue which acts on voltage-gated calcium ion channels (Mason et al., 2018), on brain activation to visual alcohol cues (Schacht et al., 2013b). This study did not find a significant main effect of the combination of medications on neural alcohol cue reactivity. There was a moderating effect of alcohol withdrawal on neural alcohol cue reactivity, such that individuals with high levels of alcohol withdrawal treated with the combination of medications displayed increased activation in the dorsal anterior cingulate cortex (dACC) in response to alcohol cues. Beck and colleagues investigated the effect of high-dose baclofen, a selective GABA\_B receptor agonist (Agabio et al., 2018), on neural activation to alcohol cues (Beck et al., 2018). Baclofen decreased activation in the OFC, amygdala, and ventral tegmental area (VTA) in response to alcohol cues, compared with placebo. Clinically, treatment with baclofen reduced relapse rates compared with placebo (Beck et al., 2018). Logge and colleagues examined the effect of low (30 mg)- and high (75 mg)-dose baclofen on neural response to alcohol cues (Logge et al., 2019). Similarly to Beck and colleagues, they found that high-dose baclofen decreased alcohol cue-elicited activation in frontal (mPFC, ACC, and dorsolateral prefrontal cortex (DLPFC)) regions compared with placebo. Moreover, in the placebo group, there was a positive correlation between percent heavy drinking days prior to the fMRI scan and alcohol cue-elicited activation in the caudate and ACC, which was not present in the high- or low-dose baclofen groups. Holla and colleagues also examined the effect of baclofen on neural response to alcohol cues (Holla et al., 2018). In contrast with the other baclofen studies, they found that baclofen increased activation in the DLPFC and ACC and decreased activation in the insula compared with a nonmedication AUD control group. Further, increases and decreases in brain activation associated with baclofen treatment were
predictive of time to relapse, such that when treated with baclofen, greater activation of the ACC when viewing alcohol cues reduced the likelihood of early lapse, whereas continued activation of the insula under baclofen increased the likelihood of early lapse (Holla et al., 2018).

The effect of dopamine stabilization through the partial dopamine agonist aripiprazole (Akbar et al., 2018) on alcohol cue-elicited brain response has also been evaluated (Han et al., 2013; Myrick et al., 2010; Schacht et al., 2018). Myrick and colleagues reported that aripiprazole blunted alcohol-cue-elicited reward responses in the left VTA and right VS and reduced heavy drinking days compared with placebo (Myrick et al., 2010). Han and colleagues investigated the effect of the combination of aripiprazole and escitalopram, a selective serotonin reuptake inhibitor (Owens et al., 2001), on neural response to alcohol cues in individuals with comorbid major depressive disorder and AUD. They found that the combination of aripiprazole and escitalopram resulted in increased activation in the ACC when viewing drinking scenes compared with escitalopram alone. Treatment with the combination of medications also resulted in a reduction in alcohol craving (Han et al., 2013). Finally, Schacht and colleagues investigated the moderating role of variation in dopamine-related genes on aripiprazole’s effect on alcohol cue-elicited brain response (Schacht et al., 2018). They found a significant interaction between medication and DAT1 genotype, such that aripiprazole reduced alcohol cue-elicited activation in the VS among 9R carriers, but increased VS activation in 10R homozygotes, compared with placebo. Furthermore, they found that in a laboratory setting, aripiprazole reduced the number of drinks consumed only in 9R carriers (Schacht et al., 2018).

Preclinical studies have indicated that receptors for corticotrophin-releasing factor 1 (CRF1, also referred to as corticotrophin-releasing hormone (CRH)) and neurokinin-1 receptor (NK1R) are critically involved in AUD and stress (Petraitis and Simpson, 2017; Spierling and Zorrilla, 2017). Two studies evaluated the effect of CRF1 receptor antagonists on modulating neural response to alcohol cues and affective stimuli (Kwako et al., 2015b; Schwandt et al., 2016). Kwako and colleagues evaluated the effect of pexacertan, a selective CRF1 antagonist, on modulating brain response to alcohol-related and affective stimuli in individuals with AUD and high levels of trait anxiety (Kwako et al., 2015b). There were no significant effects of pexacertan on neural responses to alcohol cues, negative images, or fearful faces. Furthermore, pexacertan did not impact stress-induced alcohol craving (Kwako et al., 2015b). Similarly, Schwandt and colleagues evaluated the effect of verucerfont, a selective CRF1 receptor antagonist, on modulating brain response to alcohol-related and affective stimuli in women with AUD and high levels of trait anxiety (Schwandt et al., 2016). In contrast to Kwako et al., this study reported that verucerfont significantly attenuated activation in the right amygdala in response to fearful faces compared with placebo, but did not impact neural responses to negative pictures. However, verucerfont also did not suppress stress-induced alcohol craving responses (Schwandt et al., 2016). Two studies investigated whether NK1R antagonism modulates brain responses to alcohol cues and affective stimuli (George et al., 2008; Kwako et al., 2015a). George and colleagues reported that LY686017 (now tradipitant), a NK1R antagonist, reduced activation to negative images in the insula and increased VS activation to positive images compared with placebo. Moreover, treatment with LY686017 reduced overall alcohol craving as well as reduced stress-induced alcohol craving. NK1R antagonism did not modulate neural responses to alcohol cues (George et al., 2008). In contrast, Kwako and colleagues found that aprepitant, a NK1R antagonist, potentiated ventromedial prefrontal cortex responses to negative stimuli compared with placebo in individuals with comorbid AUD and posttraumatic stress disorder (PSTD). Aprepitant did not affect stress- or alcohol-induced craving (Kwako et al., 2015a). Overall, these studies indicate that the preclinical promise of CRF1 and NK1 receptor antagonists has not translated well into the clinical population of treatment-seeking individuals with AUD.

Finally, the effect of N-methyl-D-aspartate (NMDA) modulators on neural alcohol cue reactivity has been evaluated (Kiefer et al., 2015; Langosch et al., 2012). Langosch and colleagues investigated the effect of acamprosate, an FDA-approved pharmacotherapy for AUD thought to be a glutamate modulator (Plosker, 2015), on brain responses to alcohol cues (Langosch et al., 2012). They found no significant effect of acamprosate on modulating neural alcohol cue reactivity compared with placebo. Kiefer and colleagues investigated the effect of the combination of cue exposure–based extinction training (CET), which is a psychosocial treatment for AUD, and D-cycloserine (DCS), a partial NMDA receptor agonist thought to facilitate memory consolidation (Norberg et al., 2008), on alcohol cue-elicited brain activation (Kiefer et al., 2015). The authors report a reduction in alcohol cue-elicited brain activation in the ventral and dorsal striatum in individuals treated with the combination of CET and DCS compared to those treated with CET and placebo. Furthermore, there was an interaction between pretreatment VS activation, medication, and alcohol craving, such that in individuals with high levels of alcohol craving and high pretreatment VS activation, treatment with DCS and CET was more efficacious compared with placebo (Kiefer et al., 2015).

Summary

Overall, there is considerable variability in sample selection (treatment-seeking vs. non–treatment-seeking, individuals diagnosed with AUD vs. heavy drinkers), task selection, and analytical methodology (ROI vs. whole-brain approaches) in studies investigating the neural effects of AUD pharmacotherapies administered chronically. Despite these extensive differences, a few patterns do emerge, which
are summarized in Fig. 3. Naltrexone does seem to have an effect on alcohol reward processing, with several studies reporting reductions in activation in regions associated with reward, including the VS (Bach et al., 2019; Lukas et al., 2013; Myrick et al., 2010; Schacht et al., 2017). Furthermore, 2 studies demonstrated the predictive utility of fMRI combined with pharmacotherapy for predicting clinical outcomes (Bach et al., 2019; Schacht et al., 2017). Schacht and colleagues found that individuals treated with NTX who had large reductions in VS activation to alcohol cues had the lowest amount of heavy drinking in the weeks following the fMRI scan (Schacht et al., 2017), and Bach and colleagues found that NTX-treated individuals who demonstrated high alcohol cue reactivity at baseline had a longer time to severe relapse than NTX-treated patients with low alcohol cue reactivity at baseline (Bach et al., 2019). Varenicline also shows promise as an AUD treatment and appears to impact reward and affective processing; however, there is little overlap in task selection in the reported studies which limits generalizability (Gowin et al., 2016; Schacht et al., 2014; Vatsalya et al., 2015). Two studies reported an increase in ACC activation following treatment with a GABA antagonist (Holla et al., 2018; Schacht et al., 2013b), and this increase in ACC activation after treatment has been associated with lower relapse rates (Holla et al., 2018). Aripiprazole may modulate alcohol cue-elicited brain response in the VS (Myrick et al., 2010), with some evidence indicating a pharmacogenetic interaction between dopamine-related genetic variation and aripiprazole response (Schacht et al., 2018). Medications targeting stress circuitry (CRF1 and NK1) do not show consistent effects on brain response to alcohol cues or affective stimuli, and have largely shown null effects clinically (George et al., 2008; Kwako et al., 2015a,b; Schwandt et al., 2016). Surprisingly, only 1 study has evaluated the effect of acamprosate on alcohol cue-elicited neural response (Langosch et al., 2012), which reported null effects of the medication. The combination of the pharmacotherapy DCS with CET was effective at reducing alcohol-elicited activation in the VS and dorsal striatum compared with CET alone (Kiefer et al., 2015). Moreover, DCS may work best in individuals with high craving for alcohol who demonstrate high levels of VS activation before the start of treatment. Together, these studies suggest that fMRI can be a useful tool to identify biomarkers for AUD pharmacotherapy. It is encouraging

Fig. 3. Brain circuits modulated by AUD pharmacotherapies administered chronically. The summarized findings of the review are presented for each pharmacotherapy that was investigated using a chronic dosing approach, ↓ = attenuated activation in targeted brain circuitry; ↑ = potentiated activation in targeted brain circuitry; - = mixed findings in targeted brain circuitry (attenuation, potentiation, and/or null); and ? = has not yet been investigated.
that for medications that have been studied most often, such as NTX and varenicline, a consistent pattern of results emerges. Perhaps most importantly, the literature is beginning to implicate patterns of brain response to pharmacotherapy with clinical outcomes, the gold standard of clinical care.

Single Dosing Studies of AUD Pharmacotherapies

Table 2 presents a comprehensive list of single dosing neuroimaging pharmacotherapy studies. Naltrexone is also the most commonly studied AUD pharmacotherapy using single dosing procedures and neuroimaging (Boettiger et al., 2009; Nestor et al., 2017, 2018; Savulich et al., 2017). The majority of these studies employed a double-blind, placebo-controlled, crossover design enrolling participants with AUD and a healthy control comparison group. Boettiger and colleagues investigated the effect of acute NTX on impulsive decision making in abstinent individuals with AD using a delay discounting paradigm (Boettiger et al., 2009). There was no significant interaction between group and medication conditions; however, NTX administration did increase OFC activation during decision making for “later” choices in both abstinent individuals with AD and healthy controls.

The following set of studies investigated NTX through the Imperial College Cambridge Manchester (ICCAM) platform, which is an experimental medicine approach to explore the neuropharmacology of relapse using fMRI techniques (Paterson et al., 2015). The ICCAM studies enrolled abstinent individuals with AD alone, abstinent individuals with AD and other substance use disorders (polysubstance-dependent), and a comparison group of healthy controls. Using this platform, Savulich and colleagues investigated the effect of acute NTX on negative emotion processing (Savulich et al., 2017). NTX did not significantly modulate activation in the AD-only group; however, it did reduce amygdala activation in the polysubstance-dependent group compared with the AD-only and healthy control groups. Nestor and colleagues investigated the effect of acute NTX administration on nondrug reward processing using the MID task (Nestor et al., 2017). There was no significant interaction between group and medication on nondrug reward processing. Nestor and colleagues also investigated the effect of acute NTX on the neural correlates of motor impulse control using the GNG task (Nestor et al., 2018). There was a significant interaction between group and medication condition, such that in individuals with AD alone, NTX increased activation in the OFC compared with the polysubstance-dependent group; in the polysubstance-dependent group, NTX increased activation in the anterior insula compared with the AD-only group.

Another opioid receptor antagonist nalmefene, which is a µ- and δ-opioid receptor antagonist and κ-opioid receptor partial agonist (Soyka, 2016), has been also investigated using the single dosing approach (Quelch et al., 2017). Quelch and colleagues investigated the effect of nalmefene on the neural correlates of reward processing using the MID task paired with an intravenous alcohol infusion (Quelch et al., 2017). In individuals with AUD, nalmefene reduced activation in the striatum when anticipating rewards during an alcohol infusion compared with placebo.

Two studies have investigated the effect of acute dopamine antagonism on neural responses to alcohol and nonalcohol reward processing (Hermann et al., 2006; Murphy et al., 2017). Hermann and colleagues investigated the effect of amisulpride, a D2/3 dopamine receptor antagonist (Grunder et al., 2003), on neural alcohol cue reactivity (Hermann et al., 2006). Acute treatment with amisulpride reduced alcohol cue-elicited activation in the right thalamus in individuals with AD. Using the ICCAM platform, Murphy and colleagues evaluated the effect of the drug on nondrug reward processing using the MID task, and motor impulse control, using the GNG task (Murphy et al., 2017). Regarding reward processing, there was a significant group by medication interaction during reward anticipation, such that in individuals with AD only GSK598809 increased activation in the dorsolateral PFC compared with the polysubstance and healthy control groups. There was no significant effect of the drug on the neural correlates of inhibitory control.

Modafinil, a cognitive enhancer used to treat narcolepsy (Leeman et al., 2014), has been investigated as a potential pharmacotherapy to improve impulse control in individuals with AD (Schmaal et al., 2013, 2014). Schmaal and colleagues investigated the effect of acute modafinil on response inhibition, evaluated through the SST and impulsive decision making, evaluated through a delay discounting task, using a double-blind, placebo-controlled, crossover approach. There was a significant group by medication interaction on response inhibition activation in the putamen, such that treatment with modafinil increased activation in the putamen in individuals with AD compared with placebo (Schmaal et al., 2013). Modafinil also modulated the neural correlates of impulsive decision making; in individuals with AD, acute treatment with modafinil improved impulsive decision making and increased activation in the superior frontal gyrus and decreased activation in the ventromedial PFC (Schmaal et al., 2014). It should be noted that these studies were conducted on the same participants during the same study visits; the differing number of subjects included in the substudies reflects differences in motion and task engagement for the individual tasks.

Finally, oxytocin, a neuropeptide that is implicated in social behavior (Lee and Weerts, 2016), has been investigated as a novel pharmacotherapy for AUD. Hansson and colleagues investigated the effect of acute oxytocin, administered intranasally, on neural alcohol cue reactivity in male heavy drinkers (Hansson et al., 2018). Oxytocin administration resulted in significant reductions in neural alcohol cue reactivity in the insula, cingulate, and the medial frontal gyrus, compared with placebo.
<table>
<thead>
<tr>
<th>First author, year</th>
<th>Medication, dose, duration</th>
<th>fMRI task</th>
<th>AUD N</th>
<th>Comparison group N</th>
<th>Analysis approach</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Naltrexone (NTX)</strong></td>
<td>50 mg NTX × 2 hours</td>
<td>Delay discounting</td>
<td>9 abstinent AD</td>
<td>10 healthy controls</td>
<td>Whole brain and ROI</td>
<td>No significant group × medication interaction. NTX increased activation in OFC during “later” decisions across AUD and healthy control groups.</td>
</tr>
<tr>
<td><strong>Savulich et al. (2017)</strong></td>
<td>50 mg NTX × 2 hours</td>
<td>IAPS</td>
<td>18 abstinent AD only 21 abstinent polysubstance (AD + cocaine or opioid dependence)</td>
<td>21 healthy controls</td>
<td>ROI</td>
<td>No effect of NTX on AUD-only group. NTX reduced amygdala activation in polysubstance using group compared with AUD and HC groups.</td>
</tr>
<tr>
<td><strong>Nestor et al. (2017)</strong></td>
<td>50 mg NTX × 2 hours</td>
<td>Monetary incentive delay</td>
<td>21 abstinent ADD only 25 abstinent polysubstance (AD + other drug dependence)</td>
<td>35 healthy controls</td>
<td>Whole brain</td>
<td>No significant group × medication interaction on reward processing.</td>
</tr>
<tr>
<td><strong>Nestor et al. (2018)</strong></td>
<td>50 mg NTX × 2 hours</td>
<td>Go/No-Go</td>
<td>21 abstinent AD only 25 abstinent polysubstance (AD + other drug dependence)</td>
<td>35 healthy controls</td>
<td>Whole brain</td>
<td>Significant group × medication interaction in left OFC and left anterior insula. In AUD-only individuals, NTX increased activation in OFC compared with the polysubstance group. In polysubstance users, NTX increased activation in the anterior insula compared with the AUD-only group.</td>
</tr>
<tr>
<td><strong>Nalmefene</strong></td>
<td>18 mg nalmefene × 4 hours</td>
<td>Monetary incentive delay + alcohol infusion</td>
<td>18 AUD</td>
<td>N/A</td>
<td>Whole brain and ROI</td>
<td>Nalmefene reduced activation in striatum and brainstem/cerebellum during reward processing compared with placebo while receiving an alcohol infusion.</td>
</tr>
<tr>
<td><strong>Dopamine antagonists</strong></td>
<td>400 mg amisulpride × 2 hours</td>
<td>Visual alcohol cues</td>
<td>10 abstinent AD</td>
<td>10 healthy controls</td>
<td>Whole brain</td>
<td>Amisulpride reduced activation in right thalamus to alcohol cues compared with placebo and normalized activation compared with healthy controls.</td>
</tr>
<tr>
<td><strong>Murphy et al. (2017)</strong></td>
<td>60 mg GSK5388909 × 2 hours</td>
<td>Monetary incentive delay</td>
<td>18 abstinent AD only 25 abstinent polysubstance (AD + other drug dependence)</td>
<td>33 healthy controls</td>
<td>Whole brain and ROI</td>
<td>Significant group × medication interaction in DLPFC, such that GSK5388909 increased reward response in AUD individuals more than the polysubstance or healthy control groups. No significant group × medication interaction.</td>
</tr>
<tr>
<td><strong>Modafinil</strong> Schmaal et al. (2013)</td>
<td>200 mg modafinil × 2 hours</td>
<td>Stop signal</td>
<td>16 AD</td>
<td>16 healthy controls</td>
<td>Whole brain</td>
<td>Group × medication interaction in left putamen, such that modafinil increased activation in AUD individuals compared with controls.</td>
</tr>
<tr>
<td><strong>Modafinil</strong> Schmaal et al. (2014)</td>
<td>200 mg modafinil × 2 hours</td>
<td>Delay discounting</td>
<td>14 abstinent AD</td>
<td>18 healthy controls</td>
<td>Whole brain</td>
<td>Group × medication interaction in left superior frontal gyrus and vmPFC when making “now” decisions, such that in individuals with AUD, modafinil increased activation in the SFG and decreased activation in the vmPFC compared with controls.</td>
</tr>
<tr>
<td><strong>Oxytocin</strong> Hansson et al. (2018)</td>
<td>24 IU Oxytocin (intranasal) × 45 minutes</td>
<td>Visual alcohol cues</td>
<td>12 NTS HD</td>
<td>N/A</td>
<td>Whole brain and ROI</td>
<td>Oxytocin reduced alcohol cue-elicited activation in the insula, hippocampus, cingulate gyrus, and medial frontal gyrus compared with placebo.</td>
</tr>
</tbody>
</table>

AD, alcohol dependence (DSM-IV TR diagnosis); AUD, alcohol use disorder (DSM-5 diagnosis); DLPFC, dorsolateral prefrontal cortex; fMRI, functional magnetic resonance neuroimaging; HD, heavy drinker; NTS, non-treatment-seeking; NTX, naltrexone; OFC, orbitofrontal cortex; ROI, region of interest; vmPFC, ventromedial prefrontal cortex.

*Studies using the same study population.
Together, single-administration NTX fMRI studies have largely not been effective at identifying NTX-induced modulations in neural circuitry in AUD populations. One study did report an effect of NTX on modulating neural activation during inhibitory control processing in AD individuals, with NTX increasing OFC activation in abstinent AD participants (Nestor et al., 2018). One study reported an overall effect of NTX on neural activation during a delay discounting task (i.e., brain activation changes were present in both healthy and AD groups) (Boettiger et al., 2009), while another study has found an effect of NTX on brain activation during negative emotional processing in a polysubstance using AD group (Savulich et al., 2017). Intriguingly, nalmefene, a medication whose putative mechanism is similar to NTX, was effective at reducing reward activation during nondrug reward processing combined with an alcohol infusion in individuals with AUD (Quelch et al., 2017). Modafinil appears to be effective at modulating brain response in individuals with AD during decision making and impulse control tasks (Schmaal et al., 2013, 2014). However, these findings come from 1 larger study; additional work is needed to replicate and extend upon these findings. Oxytocin also showed initial efficacy at reducing neural responses to alcohol cues in heavy social drinkers (Hansson et al., 2018). However, this pilot study enrolled a small sample of only male participants, which indicates that additional replication and more representative samples will be required. Overall, these studies call into question the future use of single-administration AUD pharmacotherapies, due to the mixed findings and wide variety of fMRI tasks employed, summarized in Fig. 4. An important conclusion emerging from the literature reviewed herein, and divided into acute and chronic administering, is that acute (or single dose) drug administration is much less reliable than chronic dosing from the viewpoint of pharmacological effects detected through functional neuroimaging. This is perhaps not surprising, given that organisms adapt to pharmacological agents and chronic dosing is most representative of clinical care models. Nonetheless, this review cautions against the use of acute administration fMRI models on the basis of these mixed results. The exception to this recommendation may be pharmacotherapies used on an as-needed (i.e., PRN) basis, such as nalmefene and oxytocin.

While the preponderance of the qualitative findings is displayed in Tables 1 and 2, organized by dosing and pharmacotherapy, readers interested in findings organized by task and targeted brain circuitry (separated by dosing) are directed to Tables S1–S5. Figures 3 and 4 also provide an integration of task-specific findings grouped by pharmacotherapy and separated by dosing.

**Recommendations for Future Research**

Overall, while the studies included in this review indicate that fMRI is a promising tool to narrow the pathway of pharmacological treatments for AUD, there are several key recommendations for improvements upon the existing...
method. These recommendations are meant to maximize the potential for success when conducting neuroimaging pharmacotherapy studies for AUD and are based on common issues identified in this review.

First, to adequately compare and contrast fMRI pharmacology studies we recommend a standardization of neuroimaging parameters and methods. In regard to neuroimaging methodology, 2 main approaches are currently used: a data-driven whole-brain method and an a priori ROI approach. Both approaches have strengths and weaknesses; the whole-brain method is useful for identifying neural circuitry modulated by a pharmacotherapy, especially in cases where the pharmacology is poorly understood; however, this approach comes at the cost of statistical power. The a priori ROI approach increases statistical power and represents a theory-driven model; this method has been successful in the case of NTX where the medication targets are known. Additionally, the ROI approach allows for a priori power calculation, whereas whole-brain studies do not. Both the ROI and the whole-brain approach can be applied to examine task-based connectivity, where the relationship between brain activity across time in specific seed regions (ROI-based approach) or across the brain (whole-brain approach) during specific task contrasts and under different medication conditions can be explored. Few published pharmacotherapy fMRI studies have employed this approach; however, as the field grows in its understanding of the complex interplay between brain circuits involved in addiction and exposure to alcohol, it is likely that functional connectivity approaches will be required to better understand the up- and downregulation of addiction-related neural circuits.

Another area which requires standardization is the timing of the collection of fMRI scans. In order to determine the causal role of a treatment on brain function, neuroimaging should be conducted both pre- and posttreatment. This approach will enable researchers to draw conclusions about neural circuitry changes directly attributable to the pharmacotherapy and will also provide opportunities for precision medicine approaches, discussed in detail below.

Neuroimaging pharmacology studies should also take into account sample selection and sample size. Several of the studies included in this review were underpowered, potentially due to ethical considerations in early stages of treatment development. In the chronic dosing studies, where results were arguably more consistent, sample size ranged from 10 to 59 individuals per treatment group. In the single dosing studies, sample size ranged from 9 to 32 individuals per treatment group, with the majority of studies being underpowered to find whole-brain treatment effects. Regarding sample selection, studies included in this review enrolled participants who were non–treatment-seeking heavy drinkers, non–treatment-seeking individuals with an AUD, treatment-seeking individuals with an AUD, and abstinent individuals with an AUD. Furthermore, studies included in this review also enrolled participants with comorbid psychiatric diagnoses (MDD and PTSD) and with high levels of anxiety. Given this heterogeneity, it is not surprising that results do not routinely converge, with the exception of NTX where similar results are seen in non–treatment-seeking and treatment-seeking samples (Bach et al., 2019; Lukas et al., 2013; Myrick et al., 2008; Schacht et al., 2017). Recent findings indicate that non–treatment seekers and treatment seekers differ on many clinical characteristics, including age, dependence severity, drinking consequences, craving, and alcohol drinking measures (Ray et al., 2017; Rohn et al., 2017). Moreover, the differences between these populations were shown to be predictive of clinical outcomes in a large behavioral pharmacological study (COMBINE study) (Ray et al., 2017), and therefore, these differences may also influence neural responses to pharmacotherapy. Given these important differences, we recommend that the field should standardize sample selection for fMRI pharmacotherapy studies. Ideally, this standardization should address treatment-seeking vs. non–treatment-seeking, AUD diagnosis requirements, alcohol consumption measures, and the date of last drinking prior to study enrollment.

Second, we recommend the standardization of fMRI task selection for AUD pharmacotherapy studies. There was significant heterogeneity in the task selection used for the studies included in this review. The most commonly used task was the alcohol cue-reactivity paradigm, which has strong face validity as a measure for AUD pharmacotherapy. However, even within this paradigm different approaches are employed which may contribute to inconsistent findings. For example, alcohol cue-reactivity studies use different modalities of alcohol cues, including pictures of alcoholic beverages, videos of alcohol, gustatory stimuli, and olfactory stimuli. Other common fMRI paradigms included the MID task, which targets nondrug reward processes, and affective processing visual stimuli sets, including affective faces and negative images. All of these paradigms/visual stimuli sets can be standardized with regard to trial duration and task contrasts analyzed. Moreover, establishing criterion validity with regard to task selection will be key for future studies. fMRI offers the ability to provide an objective measure that can predict treatment response. For example, Mann and colleagues have shown that pretreatment brain activation during an alcohol cue-reactivity task can predict treatment efficacy of NTX on relapse behavior (Mann et al., 2014). Several recent studies included in this review highlight the benefits of these treatment-prediction analyses (Bach et al., 2019; Holla et al., 2018; Schacht et al., 2017). These studies indicate that neural response to alcohol cues has criterion validity for a clinical outcome and indicates that this paradigm should be used in future studies of AUD pharmacotherapy, particularly for medications targeting reward circuitry. Moreover, additional brain–behavior relationships can and should be investigated in future studies. Measurements of alcohol craving, alcohol use, and mood are commonly collected in pharmacotherapy fMRI studies. We recommend that brain–behavior associations should
be investigated to better triangulate brain imaging findings onto behavior, particularly in the context of pharmacotherapy.

Third, we recommend studying AUD pharmacotherapies using a chronic dosing regimen. By parsing the literature into chronic and acute dosing, there was mixed support for pharmacotherapy effects in acute dosing (i.e., single dose) studies. Therefore, unless the drug is a PRN or there is another compelling reason to examine single-dose effects, it appears as though chronic dosing should be the preferred approach to combining pharmacotherapy and fMRI, although exactly how long the dosing regimen should last prior to imaging remains an open question, and may in fact vary by medication. For example, NTX blocks mu and kappa receptors at high rates and rather quickly (Weerts et al., 2008), such that acute dosing may be useful in this context. Conversely, targeting delta-opioid receptors would like to necessitate a different dosing and titration schedule. An important first step may be to ensure that the medication under study has reached steady state and is at the target clinical dosing. Lastly, it should be noted that while samples in the chronic and acute dosing studies were of similar age on average, they were quite different in their clinical characteristics; namely, acute dosing studies recruited longer-term abstinence individuals, while chronic dosing studies recruited current users or individuals with short-term abstinence.

Additionally, we recommend including neuroimaging in the context of a clinical pharmacotherapy trial. While incorporating neuroimaging into a trial will increase upfront costs, it offers substantial benefits, as it can provide both mechanistic insights into the method of action of a medication, as well as providing biomarkers for prediction of clinical outcomes. Additionally, as clinical trials are generally better-powered than small-scale fMRI trials, the inclusion of neuroimaging in such trials will provide better sample sizes and increased statistical power. In the context of clinical applications, understanding the putative mechanism of action of a given pharmacotherapy may suggest different experimental designs. For example, NTX is known to alter the subjective experience of alcohol (Ray et al., 2010); thus, an experimental design that includes alcohol administration may be ideally suited to capture these alcohol-dependent effects. Furthermore, we recommend that combined neuroimaging and pharmacogenetic evaluation be conducted whenever possible, particularly in the context of pharmacogenetic clinical trials. Several studies reviewed herein demonstrate the utility of this approach, revealing complex interactions between neural brain activation, genetic phenotype(s), and medication response (Schacht et al., 2013c, 2017, 2018). For example, Schacht and colleagues evaluated whether variation in dopaminergic genes (DAT1I variable number tandem repeat, and polymorphisms in COMT, DRD2, and DRD4) moderated the effect of aripiprazole on neural alcohol cue reactivity (Schacht et al., 2018). They found that the DATI genotype moderated medication effects, such that there were opposing effects of the medication on VS activation to alcohol cues. Due to the opposing direction of these effects, had this sample had been combined and no pharmacogenetic effect been evaluated, the authors may have concluded that the medication produces an overall null effect on brain response.

In conclusion, this qualitative review of the literature examined studies combining AUD pharmacotherapies and functional neuroimaging methods. This review documented imaging tasks, imaging methods, sample characteristics, sample sizes, and pharmacotherapy dosing. Together, findings from this review underscore the utility of fMRI for elucidating mechanisms of action of AUD pharmacotherapies and for predicting clinical response, albeit the later goal has only been pursued in a few recent studies. It appears as though the promise of functional neuroimaging applied to AUD medications development is best served in the context of clinically informative samples, dosing regimens, tasks, and analytic approaches. To that end, this review provides a series of recommendations to advance pharmacotherapy development for AUD by leveraging neuroimaging tools. Lastly, a host of novel methods is constantly being developed for neuroimaging and for data analysis broadly. Thus, it is plausible that new analytic methods, not yet represented in the current literature, may have a major impact in how fMRI is used. Examples include functional connectivity analyses (both task-based and resting state) and computational psychiatry methods leveraging fMRI data. Moreover, the data and conclusions presented in the current review are drawn from group fMRI studies. As scanners with higher signal-to-noise ratio, that is, 7T scanners, become more widely used, the field will need to move to individual-level analyses. Analytic methods notwithstanding, strong experimental rigor cannot be replaced by data analytic tools and as such, the recommendations for further standardization of fMRI studies of AUD pharmacotherapies stand as a critical next step for the field.

ACKNOWLEDGMENTS

We greatly appreciate the assistance of Catherine Trinh in the collection of publications for this review.

This research was supported by a grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to LAR (R01AA021744). LAR has received study medication from Pfizer Medicinova and consulted for GSK and Mitsubishi Tanabe.

CONFLICT OF INTEREST

None of the authors have conflicts of interest to disclose.

REFERENCES


Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at alpha 4 beta 2 and a full agonist at alpha 7 neuronal nicotinic receptors. Mol Pharmacol 70:805.


SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Reward processing studies with chronic pharmacotherapy administration.
Table S2. Affective processing studies with chronic pharmacotherapy administration.
Table S3. Reward processing studies with acute pharmacotherapy administration.
Table S4. Affective processing studies with acute pharmacotherapy administration.
Table S5. Inhibitory control studies with acute pharmacotherapy administration.